Advertisement
Organisation › Details
Axiogenesis AG
Axiogenesis is a leading provider of commercial-grade in vitro differentiated cell types derived from human induced pluripotent stem cells (iPSCs), along with validated assays which enable improved drug development. Assays for each cell type have been developed for advanced drug discovery, disease and tissue modeling, safety pharmacology, and in vitro toxicology applications. Axiogenesis' cardiac products encompass hiPSC-derived Cor.4U® cardiomyocytes and vCor.4U ventricular cardiomyocytes used in cardiac safety and HTS applications as well as isogenic FibroCor.4U electro-competent cardiac fibroblasts used in tissue modeling. The neural cell portfolio includes Peri.4U peripheral neurons (for structural and functional toxicity assays, novel neurotoxin screening), CNS.4U central nervous system cell mix (for neurotoxicity assays and CNS disease modelling), Dopa.4U dopaminergic neurons (for neurodegenerative disease models, neurotoxicity screening), and Astro.4U astrocytes (for neuronal co-culture). Axiogenesis' innovative and proprietary cell types and assays accelerate and improve drug candidate selection, lower costs and thus increase overall drug development efficiency. *
Start | 2000-11-01 established | |
Group | Evotec (Group) | |
Today | Evotec AG, Cologne (former Ncardia AG / Axiogenesis team + IP) | |
Successor | Ncardia AG | |
Industry | BIOTECH | |
Industry 2 | assay, research | |
Person | Bohlen, Heribert (Axiogenesis 201603 CEO) | |
Person 2 | Fronhoff, Bernd (Axiogenesis 201603 CFO/COO) | |
Region | Köln (Cologne) | |
Country | Germany | |
Street | 1 Nattermannallee | |
City | 50829 Köln | |
Tel | +49-221-998818-0 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | B: 11 to 50 (2013-01-07) |
* Document for »About Section«: Luxcel Biosciences Ltd.. (2/15/17). "Press Release: Luxcel Biosciences Ltd, Axiogenesis AG and BMG LABTECH GmbH Secure €2.5m European Investment to Develop and Launch Cell Metabolism Analysis Platform: »MetaCell-TM«". Cork. | ||
Record changed: 2023-12-30 |
Advertisement
More documents for Evotec (Group)
- [1] Evotec SE. (1/4/24). "Press Release: Evotec and Owkin Enter an A.I.-powered Strategic Partnership to Accelerate Therapeutics Pipeline in Oncology and I&I". Hamburg & Paris....
- [2] Evotec SE. (1/3/24). "Press Release: Evotec Announces CEO Transition. Dr. Werner Lanthaler to Step Down as CEO". Hamburg....
- [3] Evotec SE. (10/5/23). "Press Release: Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners Launch '65LAB'". Hamburg & Singapore....
- [4] Evotec SE. (7/11/23). "Press Release: Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership". Hamburg....
- [5] Evotec SE. (5/12/23). "Press Release: Evotec Publishes Annual Report 2022 and Quarterly Statement for Q1 2023". Hamburg....
- [6] Evotec SE. (5/9/23). "Press Release: Just – Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing". Hamburg & Seattle, WA....
- [7] Evotec SE. (2/10/23). "Press Release: Evotec Receives € 150 m Loan from European Investment Bank". Hamburg & Toulouse....
- [8] Evotec SE. (2/7/23). "Press Release: Laetitia Rouxel to Succeed Enno Spillner as Chief Financial Officer". Hamburg....
- [9] Formycon AG. (2/7/23). "Press Release: Enno Spillner Appointed Chief Financial Officer (CFO) of Formycon AG". Munich....
- [10] Evotec SE. (1/26/23). "Press Release: Evotec Announces Agreement with Janssen to Develop Immune-based Therapies". Hamburg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top